Biologics CDMO for mAB Market Trends, Growth, and Market Size Analysis 2035
According to Payal Rabde, who specializes in biologics, comprehensive health services, and healthcare market intelligence, with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the biologics CDMO for mAB market. The global biologics CDMO for mAB market size is calculated at USD 20.84 billion in 2025, driven by expansion of biologics pipeline, outsourcing trends, and demand for high-capacity manufacturing facilities. Her analysis highlights rising demand for flexible manufacturing services, growing clinical diseases, and technological advancements. The research also examines the competitive strategies of key industry participants, including Wuxi Biologics, Samsung Biologics, Lonza Group, Thermo Fisher Scientific, and Fujifilm Diosynth Biotechnologies, shaping the future of biologics CDMO for mAB globally.
Last Updated : 23 July 2026
Category: Biotechnology
Insight Code: 7019
Format: PDF / PPT / Excel